These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Thal LJ; Carta A; Clarke WR; Ferris SH; Friedland RP; Petersen RC; Pettegrew JW; Pfeiffer E; Raskind MA; Sano M; Tuszynski MH; Woolson RF Neurology; 1996 Sep; 47(3):705-11. PubMed ID: 8797468 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Rai G; Wright G; Scott L; Beston B; Rest J; Exton-Smith AN Curr Med Res Opin; 1990; 11(10):638-47. PubMed ID: 2178869 [TBL] [Abstract][Full Text] [Related]
5. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer's disease? Carta A; Calvani M Ann N Y Acad Sci; 1991; 640():228-32. PubMed ID: 1776743 [TBL] [Abstract][Full Text] [Related]
6. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Thal LJ; Calvani M; Amato A; Carta A Neurology; 2000 Sep; 55(6):805-10. PubMed ID: 10994000 [TBL] [Abstract][Full Text] [Related]
7. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. Calvani M; Carta A; Caruso G; Benedetti N; Iannuccelli M Ann N Y Acad Sci; 1992 Nov; 663():483-6. PubMed ID: 1482095 [No Abstract] [Full Text] [Related]
8. Acetyl-carnitine and Alzheimer's disease. Bowman BA Nutr Rev; 1992 May; 50(5):142-4. PubMed ID: 1630720 [No Abstract] [Full Text] [Related]
9. [The use of 1-acetylcarnitine in (presenile and senile) Alzheimer's disease. Preliminary results]. Acierno G Clin Ter; 1983 Apr; 105(2):135-45. PubMed ID: 6345054 [No Abstract] [Full Text] [Related]
12. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Bianchetti A; Rozzini R; Trabucchi M Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930 [TBL] [Abstract][Full Text] [Related]
13. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Pettegrew JW; Levine J; McClure RJ Mol Psychiatry; 2000 Nov; 5(6):616-32. PubMed ID: 11126392 [TBL] [Abstract][Full Text] [Related]
14. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Spagnoli A; Lucca U; Menasce G; Bandera L; Cizza G; Forloni G; Tettamanti M; Frattura L; Tiraboschi P; Comelli M Neurology; 1991 Nov; 41(11):1726-32. PubMed ID: 1944900 [TBL] [Abstract][Full Text] [Related]
15. An example of a clinical trial in patients with Alzheimer's disease: some methodological issues. Lucca U; Menasce G; Comelli M; Cizza G; Bressi S; Frattura L; Tiraboschi P; Spagnoli A Prog Clin Biol Res; 1989; 317():1301-10. PubMed ID: 2690098 [TBL] [Abstract][Full Text] [Related]
16. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Parnetti L; Abate G; Bartorelli L; Cucinotta D; Cuzzupoli M; Maggioni M; Villardita C; Senin U Drugs Aging; 1993; 3(2):159-64. PubMed ID: 8477148 [TBL] [Abstract][Full Text] [Related]
17. [Acetyl-L-carnitine (carnicetine) in the treatment of early stages of Alzheimer's disease and vascular dementia]. Gavrilova SI; Kalyn IaB; Kolykhalov IV; Roshchina IF; Selezneva ND Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(9):16-22. PubMed ID: 22027664 [TBL] [Abstract][Full Text] [Related]
18. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Passeri M; Cucinotta D; Bonati PA; Iannuccelli M; Parnetti L; Senin U Int J Clin Pharmacol Res; 1990; 10(1-2):75-9. PubMed ID: 2201659 [TBL] [Abstract][Full Text] [Related]
19. Attenuation by acetyl-L-carnitine of neurological damage and biochemical derangement following brain ischemia and reperfusion. Calvani M; Arrigoni-Martelli E Int J Tissue React; 1999; 21(1):1-6. PubMed ID: 10463134 [TBL] [Abstract][Full Text] [Related]